BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 24, 2005
View Archived Issues
Amylin Publicly Raises $176M To Fund Symlin, Exenatide Plans
Read More
Mutations In Mitochondrion Affect Prostate Cancer Risk
Read More
Schering-Plough Plans Buyout Of Platform Firm NeoGenesis
Read More
Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger
Read More
ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO
Read More
Other News To Note
Read More
Ambit Hits A Triple, Signs BMS, GSK, Pfizer To Deals
Ambit Biosciences Inc.'s super-multi-tasking approach to kinase screening bagged the company deals with three of pharma's top players - Bristol-Myers Squibb Co., GlaxoSmithKline plc and Pfizer Inc. (BioWorld Today)
Read More